NCT00687947

Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Detailed description

Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology. The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Conditions

• Familial Hemiplegic Migraine
• Migraine With Aura
• Healthy

Interventions

Type	Name	Description
DRUG	CGRP	CGRP (0.5 ug/min) infused intravenously over 20 min

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-06-02
• Last updated: 2009-08-03

Locations

1 site across 1 country: Denmark